抗菌薬市場：薬剤クラス別、投与経路別、活性スペクトル別、作用機序別、適応症別、販売拠点別、流通チャネル別-2025-2030年世界予測

抗菌薬市場は、2024年に517億7,000万米ドルと評価され、2025年には540億5,000万米ドル、CAGR 4.54%で成長し、2030年には675億9,000万米ドルに達すると予測されています。

イントロダクション

抗菌剤は長い間、微生物感染に対する重要な防御を提供する現代医学の要でした。急速な科学の進歩と進化する疾患プロファイルに特徴づけられる時代において、抗菌薬の開発と利用は、これまでと同様に極めて重要です。抗菌剤耐性という現在進行中の課題は、医薬品の研究開発における画期的な進歩と相まって、抗菌剤市場の拡大に向けた世界の注目を再び集めるきっかけとなっています。本レポートでは、抗菌薬の現状を包括的に概観し、技術革新、規制の最新情報、新たな市場機会について詳述します。読者は、抗菌療法の複雑さ、医薬品開発、市場開拓、地域別の業界力学の相互作用についての洞察を得ることができます。

抗菌薬市場の変革

抗菌薬市場は、そのダイナミクスを再構築する変革的な変化を目の当たりにしています。主な変化としては、研究開発活動の加速が挙げられ、新規化合物の生産と既存分子の再構成製剤の両方のイノベーションを推進しています。ハイスループット・スクリーニング、計算モデリング、ゲノム・アプローチなどの先端技術は、耐性株と闘うための新たな標的やメカニズムの発見に道を開いた。さまざまな地域の規制当局が、迅速な審査プロセスや承認への合理化された経路を提供することで、進化するシナリオにいち早く適応し、技術革新にさらに拍車をかけています。

これと並行して、ヘルスケアのエコシステムは、精密医療と個別化治療レジメンをますます優先するようになっています。宿主マイクロバイオームへの付随的ダメージを最小限に抑える標的抗菌薬のニーズが最前線にあります。この動向は、抗菌薬の作用機序をより深く理解するためのメカニズム研究への積極的な投資によって支えられています。加えて、併用療法や補助療法の出現は、従来の治療パラダイムに一層の洗練を加え、新たに出現した耐性メカニズムに直面しても治療が実行可能であることを保証しています。このような市場競争の変化により、市場参入戦略が再定義され、世界企業間で新たな競合が生まれると同時に、特定の患者層や感染症プロファイルに対応するニッチな治療法にも門戸が開かれています。

主なセグメンテーションの洞察

市場セグメンテーションの詳細な分析により、多面的な抗菌薬の展望に関する重要な洞察が得られます。薬剤クラス別では、治療を生化学的特性と作用機序によって分類します。このセグメンテーションは、アミノグリコシド系、β-ラクタム系、グリコペプチド系、リンコサミド系、マクロライド系、キノロン系、スルホンアミド系、テトラサイクリン系などの主要なクラスに分類され、それぞれがさらに独自の化合物によって調査しています。アミノグリコシドのカテゴリーでは、アミカシン、ゲンタマイシン、ネオマイシン、プラゾマイシン、ストレプトマイシン、トブラマイシンなどの化合物が調査され、β-ラクタムのカテゴリーでは、カルバペネム系、セファロスポリン系、モノバクタム系、ペニシリン系の化合物固有のデータが調査されます。糖ペプチドは、ダルババンシン、オリタバンシン、テイコプラニン、バンコマイシンなどの治療薬に基づいて精査され、同様の詳細な分析アプローチが、クリンダマイシン、リンコマイシンなどの薬剤を含むリンコサミド、アジスロマイシン、クラリスロマイシン、エリスロマイシン、フィダキソマイシンなどの製品を含むマクロライド、シプロフロキサシン、デラフロキサシン、ジェミフロキサシンを検査するキノロンに適用されます。さらに、スルファジアジン、スルファドキシン、スルファメトキサゾール-トリメトプリムなどの化合物をカバーするスルホンアミド、ドキシサイクリン、ミノサイクリン、テトラサイクリン、チゲサイクリンに焦点を当てたテトラサイクリンを検討することで、さらなる層が提供されます。

もう一つの重要なセグメンテーションは、投与経路を考慮することです。吸入、筋肉内、静脈内、経口、皮下、および局所的な手段によって薬剤がどのように体内に投与されるかを調べることから、市場の洞察が導かれます。各経路は、特に患者のコンプライアンスや薬物動態プロファイルと剤形を整合させる際に、独自の課題と機会をもたらします。同様に、活性スペクトルに基づくセグメンテーションは、製品を広域スペクトル剤と狭スペクトル剤に分類し、臨床上の意思決定と規制当局の承認の両方をサポートする分析上の区別となります。作用機序に基づくセグメンテーションでは、薬剤は細胞壁合成阻害、核酸合成阻害、タンパク質合成阻害、ATP合成酵素活性阻害、膜機能阻害、代謝経路阻害などの能力に基づいて分類されます。呼吸器感染症、性感染症、皮膚感染症、尿路感染症など、抗菌薬の幅広い適応症もセグメンテーションの中心です。同様に影響力を持つのが、販売時点に基づくセグメンテーションで、製品を市販薬と処方薬に区分し、流通と市場浸透に影響を与えます。最後に、販売チャネルに基づくセグメンテーションでは、オフライン販売とオンライン販売を区別し、オフラインチャネルはさらに、病院薬局と小売薬局の環境における実績によって評価されます。これらのセグメンテーションを総合すると、利害関係者が戦略を調整し、進化する市場の需要に効果的に対応できるような、確かな洞察が得られます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延と拡大により抗菌ソリューションの必要性が高まっている
    • 院内感染の発生率増加による高度な抗菌薬の必要性
    • 抗菌薬の研究開発に対する政府の取り組みの高まり
  • 抑制要因
    • 抗菌薬に関連する製品リコール問題
  • 機会
    • 薬剤処方と送達技術の進歩により、抗菌薬に新たな道が開かれる
    • 抗菌薬の推進に向けた官民連携の継続
  • 課題
    • 多剤耐性病原体に対する有効性は限られており、副作用のリスクがある
• 市場セグメンテーション分析
  • 薬物クラス：幅広い有効性と実証された安全性プロファイルにより、ベータラクタムの需要が高まっています。
  • 投与経路：投与が容易なため、経口投与の採用が増加しています。
  • 活動範囲：より正確な治療のために、狭い範囲の抗菌薬を優先する
  • 作用機序：細菌の増殖を防ぐために核酸合成を阻害する抗菌薬の必要性
  • 適応症：革新的な抗菌療法による尿路感染症管理の精度向上
  • 販売時点情報管理：市販抗菌薬の需要増加によるアクセス性の向上
  • 流通チャネル：安全な宅配サービスのため、オンラインが好まれる傾向が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 抗菌薬市場薬剤クラス別

• アミノグリコシド
  • アミカシン
  • ゲンタマイシン
  • ネオマイシン
  • プラゾマイシン
  • ストレプトマイシン
  • トブラマイシン
• ベータラクタム
  • カルバペネム
  • セファロスポリン
  • モノバクタム
  • ペニシリン
• 糖ペプチド
  • ダルババンシン
  • オリタヴァンシン
  • テイコプラニン
  • バンコマイシン
• リンコサミド
  • クリンダマイシン
  • リンコマイシン
• マクロライド
  • アジスロマイシン
  • クラリスロマイシン
  • エリスロマイシン
  • フィダキソマイシン
• キノロン
  • シプロフロキサシン
  • デラフロキサシン
  • ゲミフロキサシン
• スルホンアミド
  • スルファジアジン
  • スルファドキシン
  • スルファメトキサゾール-トリメトプリム
• テトラサイクリン
  • ドキシサイクリン
  • ミノサイクリン
  • テトラサイクリン
  • タイゲサイクリン

第7章 抗菌薬市場：投与経路別

• 吸入
• 筋肉内
• 静脈内
• オーラル
• 皮下
• トピック

第8章 抗菌薬市場活動スペクトル別

• 広域スペクトル
• 狭帯域スペクトル

第9章 抗菌薬市場作用機序別

• 細胞壁合成を阻害する
• 核酸合成を阻害する
• タンパク質合成を阻害する
• ATP合成酵素阻害剤
• 膜機能阻害剤
• 代謝経路の阻害剤

第10章 抗菌薬市場：適応症別

• 呼吸器感染症
• 性感染症
• 皮膚感染症
• 尿路感染症

第11章 抗菌薬市場販売時点情報管理

• 市販薬
• 処方薬

第12章 抗菌薬市場：流通チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第13章 南北アメリカの抗菌薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋地域の抗菌薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの抗菌薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Allecra Therapeutics GmbH
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Century Pharmaceuticals Ltd.
• Cipla Limited
• Debiopharm Group
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Entasis Therapeutics by Innoviva, Inc.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Hikma Pharmaceuticals PLC
• Iterum Therapeutics PLC
• Johnson & Johnson Services, Inc.
• Kyorin Pharmaceutical Co., Ltd.
• Lupin Limited
• Melinta Therapeutics LLC
• Merck & Co., Inc.
• Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Saphnix Life Sciences
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Limited
• Taj Pharmaceuticals Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ANTIBACTERIAL DRUGS MARKET MULTI-CURRENCY
• FIGURE 2. ANTIBACTERIAL DRUGS MARKET MULTI-LANGUAGE
• FIGURE 3. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 4. ANTIBACTERIAL DRUGS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 25. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 31. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PLAZOMICIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DALBAVANCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORITAVANCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FIDAXOMICIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DELAFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GEMIFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFADOXINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFAMETHOXAZOLE-TRIMETHOPRIM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MINOCYCLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT CELL WALL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT NUCLEIC ACID SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT PROTEIN SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 68. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITOR OF ATP SYNTHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 69. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITORS OF MEMBRANE FUNCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 70. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITORS OF METABOLIC PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 71. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 73. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 74. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 75. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 76. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 77. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 78. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 79. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 81. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 82. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 83. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 84. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 85. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 87. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 88. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 89. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 90. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 91. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 92. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 93. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 94. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 96. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 97. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 99. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 101. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 102. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 104. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 105. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 106. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 107. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 108. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 109. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 110. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 111. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 113. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 114. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 116. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 118. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 120. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 121. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 122. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 123. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 124. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 125. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 126. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 127. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 129. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 130. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 132. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 134. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 136. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 137. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 138. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 139. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 140. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 141. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 142. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 143. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 145. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 146. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 148. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 150. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 152. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 153. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 154. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 155. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 156. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 157. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 158. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 159. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 161. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 162. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 164. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 166. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 168. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 169. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 170. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 171. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 172. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 173. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 174. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 175. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 177. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 178. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 180. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 186. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 188. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 190. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 192. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 194. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 195. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 197. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 199. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 200. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 201. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 202. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 203. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 204. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 205. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 206. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 207. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 208. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 209. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 211. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 212. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 214. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 216. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 217. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 218. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 219. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 220. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 221. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 222. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 223. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 224. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 225. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 227. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 228. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 229. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 230. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 232. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 233. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 234. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 235. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 236. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 237. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 238. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 239. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 240. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 241. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 243. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 244. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 245. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 246. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 248. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 249. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 250. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 251. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 252. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 253. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 254. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 255. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 256. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 257. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 258. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 259. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 260. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 261. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 262. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 263. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 264. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 265. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 266. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 267. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 268. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 269. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 270. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 271. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 272. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 273. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 275. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 276. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 277. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 278. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 280. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 281. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 282. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 283. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 284. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 285. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 286. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 287. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 288. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 289. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 290. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 291. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 292. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 293. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 294. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 295. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 296. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 297. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 298. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 299. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 300. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 301. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 302. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 303. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 304. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 305. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 307. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 308. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 309. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 310. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 311. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 312. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 313. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 314. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 315. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 316. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 317. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 318. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 319. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 320. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 321. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 322. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 323. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 324. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 325. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
• TABLE 326. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 327. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 328. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 329. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
• TABLE 330. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
• TABLE 331. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
• TABLE 332. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
• TABLE 333. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
• TABLE 334. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
• TABLE 335. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
• TABLE 336. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
• TABLE 337. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 338. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 339. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)

TABLE 340.

The Antibacterial Drugs Market was valued at USD 51.77 billion in 2024 and is projected to grow to USD 54.05 billion in 2025, with a CAGR of 4.54%, reaching USD 67.59 billion by 2030.

Introduction

Antibacterial drugs have long been a cornerstone of modern medicine, offering critical defense against microbial infections. In an era marked by rapid scientific advances and an evolving disease profile, the development and utilization of antibacterial agents remain as crucial as ever. The ongoing challenge of antimicrobial resistance, coupled with breakthroughs in pharmaceutical research and development, has catalyzed a renewed global focus on expanding the antibacterial drugs market. This report provides a comprehensive overview of the current state of antibacterial drugs, detailing technological innovations, regulatory updates, and emerging market opportunities. Readers will gain insight into the complexity of antibacterial therapies and the interplay between drug development, market segmentation, and regional industry dynamics.

Transformative Shifts in the Landscape

The antibacterial drugs market has witnessed transformative changes that are reshaping its dynamics. Key shifts include an acceleration in research and development activities that are driving innovations across the production of both novel compounds and restructured formulations of existing molecules. Advanced technologies such as high-throughput screening, computational modeling, and genomic approaches have paved the way for the discovery of new targets and mechanisms to combat resistant strains. Regulatory agencies across different regions are adapting faster to the evolving scenario by offering expedited review processes and streamlined pathways to approval, further spurring innovation.

In parallel, the healthcare ecosystem is increasingly prioritizing precision medicine and individualized therapeutic regimens. The need for targeted antibacterial agents that minimize collateral damage to the host microbiome is at the forefront. This trend is supported by robust investments in mechanistic studies that provide greater insight into the modes of action of antibacterial drugs. In addition, the emergence of combination therapies and adjuvant treatments has added a layer of sophistication to traditional treatment paradigms, ensuring that therapies remain viable even in the face of emerging resistance mechanisms. Collectively, these transformative shifts have redefined market entry strategies and built new layers of competition among global players, while simultaneously opening the door for niche interventions that cater to specific patient demographics and infection profiles.

Key Segmentation Insights

An in-depth analysis of market segmentation provides critical insight into the multifaceted antibacterial drugs landscape. The drug class segmentation categorizes treatments by the biochemical properties and mechanisms of action. This segmentation is broken down into major classes such as Aminoglycosides, Beta-Lactams, Glycopeptides, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines; each of which is further studied by its unique compounds. Within the Aminoglycosides category, compounds including Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin are examined, while the Beta-Lactams category delves into Compound-specific data for Carbapenems, Cephalosporins, Monobactams, and Penicillins. Glycopeptides are scrutinized based on therapies such as Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin, and similar detailed analytical approaches are applied to Lincosamides with agents like Clindamycin and Lincomycin, Macrolides with products including Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin, followed by Quinolones examining Ciprofloxacin, Delafloxacin, and Gemifloxacin. Additional layers are provided by examining Sulfonamides, which cover compounds such as Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim, together with Tetracyclines that focus on Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Another important segmentation considers routes of administration. Market insights are deduced from examining how drugs are delivered into the system via Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical means. Each route presents unique challenges and opportunities, particularly when aligning dosage forms with patient compliance and pharmacokinetic profiles. Similarly, segmentation based on the spectrum of activity categorizes products as Broad-Spectrum versus Narrow-Spectrum agents, an analytical distinction that supports both clinical decision-making and regulatory approvals. Further refinement is seen in segmentation according to mechanism of action, where drugs are grouped based on their ability to inhibit cell wall synthesis, nucleic acid synthesis, protein synthesis, ATP synthase activity, or affect membrane functions and metabolic pathways. The wide-ranging indications for antibacterial drugs are also central to segmentation, with clinical applications spanning Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections. Equally influential is the segmentation based on the point of sale, delineating products as Over-The-Counter or Prescription Drugs, which affects distribution and market penetration. Finally, a segmentation based on the distribution channel distinguishes between Offline and Online sales, with Offline channels being further evaluated by their performance in Hospital Pharmacy and Retail Pharmacy environments. These segmentation dimensions collectively provide robust insights that enable stakeholders to tailor their strategies and respond effectively to the evolving market demands.

Based on Drug Class, market is studied across Aminoglycosides, Beta-Lactams, Glycopeptide, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines. The Aminoglycosides is further studied across Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin. The Beta-Lactams is further studied across Carbapenems, Cephalosporins, Monobactams, and Penicillins. The Glycopeptide is further studied across Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin. The Lincosamides is further studied across Clindamycin and Lincomycin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin. The Quinolones is further studied across Ciprofloxacin, Delafloxacin, and Gemifloxacin. The Sulfonamides is further studied across Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim. The Tetracyclines is further studied across Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical.

Based on Spectrum of Activity, market is studied across Broad-Spectrum and Narrow-Spectrum.

Based on Mechanism of Action, market is studied across Inhibit Cell Wall Synthesis, Inhibit Nucleic Acid Synthesis, Inhibit Protein Synthesis, Inhibitor of ATP Synthase, Inhibitors of Membrane Function, and Inhibitors of Metabolic Pathways.

Based on Indication, market is studied across Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections.

Based on Point of Sale, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.

Key Regional Insights

The antibacterial drugs market exhibits significant heterogeneity across different global regions, reinforcing the need for tailored strategies that accommodate local dynamics. In the Americas, advanced healthcare infrastructure and heightened public awareness about antimicrobial resistance have driven significant investment in research, fostering a dynamic market characterized by rapid adoption of innovative therapies. Meanwhile, Europe, Middle East & Africa has witnessed a consolidation of regulatory policies and a strategic focus on combating resistance through coordinated public health initiatives and cross-border collaborations. Regulatory frameworks in these regions promote accelerated approvals for breakthrough technologies while ensuring that safety and efficacy remain paramount. Across Asia-Pacific, rapid economic growth, coupled with increasing healthcare expenditures and expanding access to advanced medical practices, has intensified the demand for both new and improved antibacterial agents. In these regions, the burgeoning middle class and improved health literacy have collectively encouraged wider use of both prescription and over-the-counter treatments. These regional insights underscore the importance of considering cultural, economic, and regulatory differences when devising market entry and expansion strategies in the antibacterial drugs domain.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The antibacterial drugs market is marked by the active involvement of several key companies, each contributing to the industry's forward momentum through a blend of innovation, strategic mergers, and robust product portfolios. Major players such as Abbott Laboratories, AbbVie Inc., and Allecra Therapeutics GmbH continue to invest heavily in cutting-edge research while expanding their product offerings. Astellas Pharma Inc. and AstraZeneca PLC, with their rich histories and extensive networks, consistently drive market penetration through innovative therapeutic strategies. Bausch Health Companies Inc. and Bayer AG have strengthened their positions by harnessing diagnostic advancements that enhance treatment specificity, while Bristol-Myers Squibb Company and Century Pharmaceuticals Ltd. maintain their commitment to broadening therapeutic horizons. Companies like Cipla Limited and Debiopharm Group couple extensive market reach with robust research endeavors. Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and Entasis Therapeutics by Innoviva, Inc. have also cut a niche for themselves by concentrating on targeted antibacterial solutions, ensuring that diverse patient needs are met. F. Hoffmann-La Roche AG and GlaxoSmithKline PLC continue to be stalwarts of the industry, offering a wide range of products supported by significant research investments. Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, and Iterum Therapeutics PLC have further diversified the competitive landscape by merging traditional practices with modern science. Johnson & Johnson Services, Inc. along with Kyorin Pharmaceutical Co., Ltd., Lupin Limited, and Melinta Therapeutics LLC also play pivotal roles, influencing global trends and ensuring product accessibility. The contributions of Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, and Pfizer Inc. are pivotal in setting benchmarks for excellence, with Sanofi S.A. and Saphnix Life Sciences strengthening the research interface between academia and the pharmaceutical industry. Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd. round off the cohort of influential companies that continuously shape market trends and propel innovative antibacterial therapeutics.

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allecra Therapeutics GmbH, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Century Pharmaceuticals Ltd., Cipla Limited, Debiopharm Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Iterum Therapeutics PLC, Johnson & Johnson Services, Inc., Kyorin Pharmaceutical Co., Ltd., Lupin Limited, Melinta Therapeutics LLC, Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Saphnix Life Sciences, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders in the antibacterial drugs market are encouraged to adopt a multi-pronged strategic approach in response to the continuously evolving landscape. First, stakeholders must significantly increase investments in basic and translational research targeting emerging resistance patterns, harnessing modern technologies that accelerate compound discovery and the development of efficacy-enhancing formulations. A close alliance with academic institutions and biotechnology innovators will be crucial to translating research insights into viable products. Second, companies should streamline their regulatory interphase processes and foster advocacy channels with government bodies to secure accelerated approvals without compromising on safety or efficacy benchmarks. This collaborative approach will be particularly vital in regions where regulatory frameworks are undergoing rapid transitions.

In addition, an optimized segmentation strategy can serve as a competitive differentiator. Organizations should invest in sophisticated market analytics to track evolving patient and prescriber needs, thereby allowing them to refine product portfolios based on drug class, route of administration, and spectrum of activity. Tailoring therapeutic solutions across diverse indications such as respiratory, urinary, skin, and sexually transmitted infections will enhance market relevance. Moreover, one should also focus on mechanisms of action as an integral segmentation tool, categorizing treatments according to their precision in inhibiting pathogen structures, metabolic pathways, or other critical processes. This granularity not only informs targeted marketing campaigns but also assists in achieving regulatory endorsements.

A forward-thinking distribution strategy is equally critical. Industry leaders should leverage both offline and online channels to broaden market reach while ensuring that product quality and patient safety remain uncompromised. Strategic alliances with hospital pharmacies and retail networks can drive penetration in traditionally robust offline sectors, while collaborative digital initiatives can capture the growing segment of online buyers. Finally, a clear focus on sustainability, patient-centric outcomes, and ethical drug promotion practices will build trust with healthcare professionals and end-consumers alike. Embracing these recommendations will empower industry leaders to not only navigate the complex antibacterial landscape but also to seize opportunities for sustainable growth and competitive advantage.

Conclusion

In conclusion, the antibacterial drugs market is at a pivotal juncture, driven by a synthesis of scientific innovation, regulatory reform, and robust market segmentation. The evolving landscape has redefined research paradigms and spurred the growth of innovative therapies that effectively challenge drug-resistant pathogens. A comprehensive understanding of segmentation-across drug classes, administration routes, spectrum of activity, mechanisms of action, clinical indications, points of sale, and distribution channels-proves vital to navigating this multifaceted market. The regional disparities and specific market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific further underscore the importance of localized and adaptive strategies.

The collective efforts of leading companies have paved the way for advancements that not only fulfill current market needs but also anticipate future trends. With a focus on strategic investments, partnerships, and technological integration, the antibacterial drugs landscape is poised for robust growth, enabling providers to deliver more precise and effective treatments. Ultimately, the synthesis of detailed market insights and actionable recommendations equips stakeholders with the necessary framework to navigate the ongoing challenges and tap into emerging growth opportunities in a competitive environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence and spread of infectious diseases enhancing the need for antibacterial solutions
    • 5.1.1.2. Increasing incidence of hospital-acquired infections need for advanced antibacterial drugs
    • 5.1.1.3. Rising government initiatives for antibacterial drug research and development
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall issue associated with antibacterial drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug formulation and delivery technology opening new avenues for antibacterial drugs
    • 5.1.3.2. Ongoing public-private collaboration for advancement of antibacterial drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Limited efficacy against multi-drug resistant pathogens and risk of adverse side effects
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing need of Beta-Lactams due to their broad-spectrum efficacy, and proven safety profile
  • 5.2.2. Route of Administration: Rising adoption of oral antibacterial drugs due to their ease of administration
  • 5.2.3. Spectrum of Activity: Prefernce for narrow-spectrum antibacterial drugs for more precise treatment
  • 5.2.4. Mechanism of Action: Need for an antibacterial drug that inhibits nucleic acid synthesis to prevent bacteria from proliferating
  • 5.2.5. Indication: Advancing precision in urinary tract infection management through innovative antibacterial therapies
  • 5.2.6. Point of Sale: Growing demand for over-the-counter antibacterial drug to enhancing accessibility
  • 5.2.7. Distribution Channel: Rising preference for online to secure home delivery services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Aminoglycosides
  • 6.2.1. Amikacin
  • 6.2.2. Gentamicin
  • 6.2.3. Neomycin
  • 6.2.4. Plazomicin
  • 6.2.5. Streptomycin
  • 6.2.6. Tobramycin
• 6.3. Beta-Lactams
  • 6.3.1. Carbapenems
  • 6.3.2. Cephalosporins
  • 6.3.3. Monobactams
  • 6.3.4. Penicillins
• 6.4. Glycopeptide
  • 6.4.1. Dalbavancin
  • 6.4.2. Oritavancin
  • 6.4.3. Teicoplanin
  • 6.4.4. Vancomycin
• 6.5. Lincosamides
  • 6.5.1. Clindamycin
  • 6.5.2. Lincomycin
• 6.6. Macrolides
  • 6.6.1. Azithromycin
  • 6.6.2. Clarithromycin
  • 6.6.3. Erythromycin
  • 6.6.4. Fidaxomicin
• 6.7. Quinolones
  • 6.7.1. Ciprofloxacin
  • 6.7.2. Delafloxacin
  • 6.7.3. Gemifloxacin
• 6.8. Sulfonamides
  • 6.8.1. Sulfadiazine
  • 6.8.2. Sulfadoxine
  • 6.8.3. Sulfamethoxazole-Trimethoprim
• 6.9. Tetracyclines
  • 6.9.1. Doxycycline
  • 6.9.2. Minocycline
  • 6.9.3. Tetracycline
  • 6.9.4. Tigecycline

7. Antibacterial Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalation
• 7.3. Intramuscular
• 7.4. Intravenous
• 7.5. Oral
• 7.6. Subcutaneous
• 7.7. Topical

8. Antibacterial Drugs Market, by Spectrum of Activity

• 8.1. Introduction
• 8.2. Broad-Spectrum
• 8.3. Narrow-Spectrum

9. Antibacterial Drugs Market, by Mechanism of Action

• 9.1. Introduction
• 9.2. Inhibit Cell Wall Synthesis
• 9.3. Inhibit Nucleic Acid Synthesis
• 9.4. Inhibit Protein Synthesis
• 9.5. Inhibitor of ATP Synthase
• 9.6. Inhibitors of Membrane Function
• 9.7. Inhibitors of Metabolic Pathways

10. Antibacterial Drugs Market, by Indication

• 10.1. Introduction
• 10.2. Respiratory Infections
• 10.3. Sexually Transmitted Infections
• 10.4. Skin Infections
• 10.5. Urinary Tract Infections

11. Antibacterial Drugs Market, by Point of Sale

• 11.1. Introduction
• 11.2. Over-The-Counter Drugs
• 11.3. Prescription Drugs

12. Antibacterial Drugs Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
  • 12.2.1. Hospital Pharmacy
  • 12.2.2. Retail Pharmacy
• 12.3. Online

13. Americas Antibacterial Drugs Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antibacterial Drugs Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antibacterial Drugs Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Oxford Drug Design secures GBP 1M funding to advance uUTI therapeutics
  • 16.3.2. FDA approval of Emblaveo for resistant gram-negative infections
  • 16.3.3. CARB-X invests in innovative peptide antibiotic targeting gram-negative bacteria
  • 16.3.4. Wockhardt secures CDSCO approval for Miqnaf for innovative CABP treatment
  • 16.3.5. Zai Lab and Pfizer forge strategic collaboration on novel antibacterial drug XACDURO
  • 16.3.6. FDA approves ORLYNVAH for uncomplicated urinary tract infections
  • 16.3.7. Orchid Pharma partner with Cipla Unite to launch new antibiotic in India
  • 16.3.8. Allecra Therapeutics and Acino secure exclusive licensing deal to commercialize EXBLIFEP antibiotic
  • 16.3.9. Lupin Launches generic Doxycycline injection in US
  • 16.3.10. FDA approves Zevtera for multiple bacterial infections
  • 16.3.11. Lupin secures FDA approval for generic doxycycline injection
  • 16.3.12. Basilea acquires novel preclinical antibiotics program from Spexis
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. Pfizer Inc.
  • 16.4.2. Lupin Limited
  • 16.4.3. Cipla Limited
  • 16.4.4. Glenmark Pharmaceuticals Limited

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Allecra Therapeutics GmbH
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bausch Health Companies Inc.
• 7. Bayer AG
• 8. Bristol-Myers Squibb Company
• 9. Century Pharmaceuticals Ltd.
• 10. Cipla Limited
• 11. Debiopharm Group
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Eli Lilly and Company
• 14. Entasis Therapeutics by Innoviva, Inc.
• 15. F. Hoffmann-La Roche AG
• 16. GlaxoSmithKline PLC
• 17. Glenmark Pharmaceuticals Limited
• 18. Hikma Pharmaceuticals PLC
• 19. Iterum Therapeutics PLC
• 20. Johnson & Johnson Services, Inc.
• 21. Kyorin Pharmaceutical Co., Ltd.
• 22. Lupin Limited
• 23. Melinta Therapeutics LLC
• 24. Merck & Co., Inc.
• 25. Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
• 26. Novartis AG
• 27. Pfizer Inc.
• 28. Sanofi S.A.
• 29. Saphnix Life Sciences
• 30. Shionogi & Co., Ltd.
• 31. Sun Pharmaceutical Industries Limited
• 32. Taj Pharmaceuticals Limited
• 33. Teva Pharmaceutical Industries Ltd.